Table 1 The baseline characteristics of identified studies and involved patients
Study | Study design | Region | Sample size | Mean age (years) | Male (%) | Hypertension (%) | CAD (%) | MS (%) | Prior AD (%) | DM (%) | Aneurysm (%) | Disease status | Treated aortic segments | Intervention | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dialetto 2005 [22] | Retro | Italy | 56 | 58.7 | 83.9 | 80.4 | NA | NA | 1.8 | NA | NA | Acute | Unclear | TEVAR; OMT | 18.1 |
Hsu 2005 [23] | Retro | China | 107 | 58.4 | 82.0 | NA | NA | 2.8 | NA | NA | NA | Acute | Unclear | OSR; OMT | 36.1 |
Tsai 2006 [24] | Retro | 11 countries | 242 | 62.1 | 69.0 | 70.2 | NA | 3.3 | 7.0 | 5.0 | 15.3 | Acute | Arch involvement: 12 | OSR; TEVAR; OMT | 27.6 |
Nienabler 2009 [25] | Pro | Germany, Italy, France | 140 | 60.2 | 84.3 | 12.9 | NA | 1.4 | NA | 7.9 | NA | Acute and subacute | Descending thoracic aorta: 13 | TEVAR; OMT | 24.0 |
Patel 2009 [26] | Retro | USA | 69 | 65.9 | 59.4 | 73.9 | 26.1 | NA | 13.0 | 11.6 | 31.9 | Acute | Arch aorta: 46; descending aorta: 33 | OSR; TEVAR | 37.4 |
Chemelli-Steingruber 2010 [27] | Retro | Austria | 88 | 64.6 | 75.0 | 78.4 | 23.9 | NA | NA | 8.0 | NA | Acute | Unclear | TEVAR; OMT | 33.0–36.0 |
Garbade 2010 [28] | Retro | Germany | 135 | 65.0 | 74.8 | 94.1 | NA | NA | NA | 19.3 | 73.3 | Acute | Arch involvement: 5; descending aorta: 131 | OSR; TEVAR; OMT | 36.9 |
Mastroroberto 2010 [29] | Retro | Italy | 24 | 72.4 | 62.5 | 79.2 | 8.3 | NA | 8.3 | 12.5 | NA | Acute | Unclear | OSR; TEVAR | 47.2 |
Zeeshan 2010 [30] | Retro | USA | 77 | 59.6 | 70.1 | 79.2 | 16.9 | NA | NA | 13.0 | 18.2 | Acute | Unclear | OSR; TEVAR; OMT | 37.0 |
Sachs 2010 [31] | Retro | USA | 50,00 | 60.7 | 65.6 | 67.7 | 3.7 | NA | NA | 7.6 | NA | Acute and subacute | Unclear | OSR; TEVAR | 36.0 |
Conrad 2010 [32] | Retro | USA | 2,701 | 70.9 | 57.8 | NA | NA | NA | NA | NA | NA | Acute and subacute | Descending aorta | OSR; TEVAR | 60.0 |
Narayan 2011 [33] | Retro | UK | 84 | 56.7 | 75.0 | 50.0 | 8.3 | 4.8 | NA | 2.4 | 48.8 | Acute and subacute | Descending aorta | OSR; TEVAR | 24.4 |
Nozdrzykowski 2013 [34] | Retro | Germany | 80 | 63.0 | 73.7 | 98.8 | 21.3 | 5.0 | 27.5 | 20.0 | 66.2 | Acute | Descending aorta | OSR; TEVAR; OMT | 42.0 |
Wilkinson 2013 [35] | Retro | USA | 73 | 66.2 | 63.0 | 80.8 | 26.0 | NA | 24.7 | 11.0 | 100.0 | Acute and subacute | Arch aorta: 57; descending aorta: 32 | OSR; TEVAR | 27.7 |
Shah 2014 [36] | Retro | USA | 4,706 | 67.0 | 55.0 | NA | NA | NA | NA | NA | NA | Acute | Unclear | TEVAR; OMT | 24.0–60.0 |
Brunkwall 2014 [37] | Pro | UK | 61 | 63.0 | 78.7 | NA | NA | NA | NA | NA | NA | Acute | Descending aorta | TEVAR; OMT | 12.0 |
Afifi 2015 [38] | Retro | USA | 442 | 60.2 | 62.0 | NA | NA | NA | NA | NA | NA | Acute | Descending aorta | OSR; TEVAR; OMT | 55.2 |
Chou 2015 [39] | Retro | China | 1,661 | 58.5 | 70.3 | 71.8 | NA | NA | NA | 8.8 | NA | Acute and subacute | Descending aorta | OSR; TEVAR | 48.0 |
Qin 2016 [40] | Retro | China | 338 | 60.7 | 89.3 | 47.0 | 11.5 | NA | NA | 10.4 | NA | Acute | Descending aorta: 34; extended to abdominal aorta: 304 | TEVAR; OMT | 29.9–39.5 |
Song 2016 [41] | Retro | China | 252 | 53.6 | 81.7 | 76.6 | 3.6 | 0.8 | NA | 6.7 | 2.8 | Acute | Descending aorta | TEVAR; OMT | 60.0 |
Zhu 2016 [42] | Retro | China | 118 | 52.7 | 72.9 | 93.2 | 30.5 | NA | NA | 9.3 | NA | Acute and subacute | Descending aorta: 63; arch aortic: 43 | OSR; TEVAR | 56.0 |
Iannuzzi 2018 [43] | Retro | USA | 9,165 | 66.0 | 60.8 | 66.6 | NA | NA | NA | 12.4 | NA | Acute | Unclear | OSR; TEVAR; OMT | 18.0–27.6 |
Lou 2018 [44] | Retro | USA | 318 | 57.7 | 67.3 | 92.8 | NA | 1.6 | NA | 15.7 | NA | Acute | Unclear | OSR; TEVAR; OMT | 27.6 |
Xiang 2021 [45] | Retro | China | 357 | 54.4 | 79.6 | 64.7 | 7.6 | NA | NA | 4.5 | NA | Acute | Descending aorta | TEVAR; OMT | 38.4–45.6 |
Wei 2022 [46] | Pro | China | 90 | 49.7 | 66.7 | 54.4 | 4.4 | NA | NA | 7.8 | NA | Acute | Descending aorta | TEVAR; OMT | 24.0 |
Tang 2023 [47] | Retro | China | 729 | 54.6 | 85.5 | 79.7 | 9.6 | 0.6 | NA | 7.5 | NA | Acute and subacute | Unclear | TEVAR; OMT | 58.9 |
Tian 2023 [48] | Retro | China | 105 | 46.0 | 82.9 | 94.3 | 4.8 | NA | NA | 2.9 | 1.9 | Acute and subacute | Unclear | OSR; TEVAR | 12.0 |
Lou 2023 [49] | Retro | USA | 146 | 57.1 | 67.1 | 91.1 | NA | NA | NA | 11.6 | NA | Acute | Descending aorta, abdominal aorta | TEVAR; OMT | 51.6 |
Weissler 2023 [50] | Retro | USA | 7,105 | 75.7 | 44.2 | 35.7 | 17.9 | NA | NA | 8.6 | NA | Acute | Unclear | TEVAR; OMT | 60.0 |
Ahmad 2024 [51] | Retro | Germany | 53 | 61.1 | 58.5 | 92.5 | 11.3 | NA | NA | 0.0 | NA | Acute and subacute | Unclear | TEVAR; OMT | 26.0 |
Krebs 2024 [52] | Retro | USA | 159 | 59.0 | 77.0 | 82.0 | 6.0 | NA | NA | 18.0 | NA | Acute | Unclear | TEVAR; OMT | 36.0 |